Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Gains from Investment Securities (2020 - 2025)

Rapid Micro Biosystems' Gains from Investment Securities history spans 6 years, with the latest figure at $22000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 12.0% year-over-year to $22000.0; the TTM value through Sep 2025 reached $147000.0, down 1.34%, while the annual FY2024 figure was $150000.0, 0.66% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $22000.0 at Rapid Micro Biosystems, up from $9000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.2 million in Q4 2022 and bottomed at -$27000.0 in Q2 2022.
  • The 5-year median for Gains from Investment Securities is $23500.0 (2024), against an average of $521658.3.
  • The largest annual shift saw Gains from Investment Securities surged 769.03% in 2022 before it crashed 212.5% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $833000.0 in 2021, then soared by 769.03% to $7.2 million in 2022, then plummeted by 98.29% to $124000.0 in 2023, then rose by 0.81% to $125000.0 in 2024, then tumbled by 82.4% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Gains from Investment Securities are $22000.0 (Q3 2025), $9000.0 (Q2 2025), and -$9000.0 (Q1 2025).